Effectiveness and safety of SOF/VEL containing rescue therapy in treating chronic HCV-GT4 patients previously failed NS5A inhibitors-based DAAs

Egyptian Liver Journal

Table 3 Changes in laboratory data at the end of treatment in comparison to its baseline according to the treatment regimen

Variables	SOF/VEL + RBV (n = 75)		P value	SOF/VEL/VOX (n = 75)		P value
Variables	Baseline	EOT	P value	Baseline	EOT	P value
Hemoglobin (g/L)	12.98 ± 1.77	11.39 ± 1.34	< 0.001	13.75 ± 1.51	13.15 ± 1.33	< 0.001
W.B.C (10³/mm³)	5.36 ± 2.09	6.48 ± 4.41	0.07	6.36 ± 2.31	5.81 ± 1.51	0.06
Platelets (10³/mm³)	119 ± 41	167 ± 49	< 0.001	232 ± 58	236 ± 64	0.57
ALT (U/L)	63 ± 36	34 ± 11	< 0.001	50 ± 36	32 ± 11	< 0.001
AST (U/L)	77 ± 36	30 ± 12	< 0.001	43 ± 22	27 ± 9	< 0.001
Albumin (g/dL)	1.43 ± 0.75	1.02 ± 0.25	< 0.001	0.71 ± 0.30	0.86 ± 0.24	< 0.001
Bilirubin (umol/L)	3.25 ± 0.53	3.60 ± 0.39	< 0.001	4.27 ± 0.40	4.11 ± 0.45	0.02